Darier disease (DD) is an autosomal dominant skin disorder caused by mutations in ATP2A2 encoding the sarco/endoplasmic reticulum Ca 2+ ATPase Isoform 2 (SERCA2 Combining our data with the existing literature, the rate of LGD mutations was found to be significantly higher among DD cases/families with bipolar disorder, schizophrenia, or affective psychosis (p = .011). We also found a significant relationship between mutations located in the S4-M4 region of the protein and the presence of a severe neuropsychiatric phenotype (p = .032).
| INTRODUCTION
Darier disease (DD) is a rare autosomal dominant inherited skin disorder with an estimated average prevalence of between 1 in 100,000 and 30,000 (Svendsen & Albrectsen, 1959; Tavadia, Mortimer, & Munro, 2002) and usually presents in the second decade with no sex difference (Burge & Wilkinson, 1992) . It is characterized by hyperkeratotic papules in seborrheic areas, palmo-plantar pits, and nail dystrophy. DD is inherited with a high penetrance although the phenotypic expression is variable (Munro, 1992) .
The disease is caused by mutations in the gene ATP2A2 (Sakuntabhai, Ruiz-Perez, et al., 1999) which encodes the sarco/endoplasmic reticulum (ER) Ca 2+ ATPase Isoform 2 (SERCA2), a calcium pump located in the ER membrane which plays a key role in Ca The co-occurrence of neuropsychiatric features, including depression, bipolar disorder, epilepsy, and learning difficulties, with DD has frequently been reported (Burge & Wilkinson, 1992; Denicoff, Lehman, Rubinow, Schmidt, & Peck, 1990 ; Dodiuk-Gad et al., 2014, 2016; Gordon-Smith et al., 2010; Medansky & Woloshin, 1961; Ringpfeil et al., 2001) . The nature of this co-occurrence has long been debated in the literature with a number of potential explanations being put forward. A seemingly plausible explanation is that the high psychiatric morbidity observed in DD is a direct psychological consequence of having a chronic skin disorder. However, our previous investigations into the neuropsychiatric phenotype in DD and the work of others have not found any significant relationships between psychiatric phenotypes and DD clinical features including disease severity, suggesting this argument alone cannot account for the association (Dodiuk-Gad et al., 2016; Gordon-Smith et al., 2010) .
In recent years, studies have found evidence of a population-level association between DD and psychiatric disorders-specifically mood disorders, including bipolar disorder, and schizophrenia (Cederlöf, Bergen, et al., 2015; Dodiuk-Gad et al., 2016; Gordon-Smith et al., 2010) .
This included a matched cohort study based on Swedish national registers that found individuals with DD had a 4.3 and 2.3 times higher risk of bipolar disorder and schizophrenia, respectively, than individuals in the general population (Cederlöf, Bergen, et al., 2015) . These findings suggest that mutations in ATP2A2 have pleiotropic effects in the skin and brain and confer susceptibility to neuropsychiatric features. This theory would be strongly supported by evidence of genotype-phenotype relationships between ATP2A2 mutation type and co-occurrence of neuropsychiatric phenotypes.
To date, a small number of studies have examined genotypephenotype correlations with the neuropsychiatric phenotypes observed in DD (Bchetnia et al., 2009; Dodiuk-Gad et al., 2016; Jacobsen et al., 1999; Nellen et al., 2016; Ringpfeil et al., 2001; RuizPerez et al., 1999; with no clear and consistent correlations being identified. Difficulties in establishing these relationships may be because of a number of reasons including small sample sizes (ranging from 8 to 49 cases) and the use of diverse methods to measure neuropsychiatric phenotypes. The lack of consistent application of any standardized method of grouping the types of mutations has also been a major methodological impedi- Jacobsen et al., 1999) . However, no other genotype-phenotype associations between mutation location along the primary structure of the gene and the presence of neuropsychiatric features have been reported in other samples (Dodiuk-Gad et al., 2016; Nellen et al., 2016; Ringpfeil et al., 2001 ) including the recent literature survey (Nakamura et al., 2016) .
The authors of the survey noted that this lack of association would be reasonable as LGD mutations in any exon could result in similar molecular consequences.
We have previously reported a systematic investigation of the neuropsychiatric characteristics in a large U.K. sample of unrelated individuals with DD (Gordon-Smith et al., 2010), and more recently reported the disease causing sequence variants of ATP2A2 within this large sample (Green et al., 2013) . Although these mutations were included in the recent analysis by Nakamura et al. (2016) , the associated neuropsychiatric phenotypes were unknown to the authors at the time. 
| Neuropsychiatric assessment
Neuropsychiatric assessments were conducted in a single session by a trained research psychologist (KGS). Psychiatric symptomatology, including history of suicidal thoughts/attempts, was measured using an adapted version of Schedules for Clinical Assessment in Neuropsychiatry interview (Wing et al., 1990 
| ATP2A2 variant identification
A DNA sample was obtained from 95 individuals. Sixty-six potentially pathogenic mutations in ATP2A2 were identified in 74 individuals. No potentially pathogenic variant in ATP2A2 was identified in the remaining 21 individuals. One of the five remaining individuals from whom a sample was not collected had taken part in a previous study (Sakuntabhai, Ruiz-Perez, et al., 1999 ) from which the potential pathogenic variant was supplied. For further details on the identification of mutations, see our previous publication (Green et al., 2013) .
| Genotype-phenotype correlations
According to the definitions used in a recent study (Nakamura et al., 2016) , mutations were classified as either LGD (frameshift insertions/ deletions, mutations predicted to alter a splice codon, nonsense mutations, gain of stop codon, or loss of start codon) or PA (missense or inframe-insertion/deletions).
Rates of LGD and PA mutations were compared between individuals stratified according to the presence or absence of each of the following key lifetime neuropsychiatric features:
1. Any neuropsychiatric phenotype.
2. Any psychiatric disorder meeting DSM-IV criteria.
3. Contact with a neurologist or neurological procedure.
4. Suicide attempt.
5. Severe neuropsychiatric phenotype (bipolar disorder, schizophrenia, or affective psychosis).
All mutations detected were mapped onto a schematic diagram of the SERCA2b protein to look for evidence of possible clustering of mutations according to occurrence within individuals of similar neuropsychiatric features.
| Combined analysis with existing literature
We combined our sample with the previously reported DD cases/families in the literature with an identified Darier causing mutation (n = 384 including the current sample).
Within the combined sample, we 1. Compared rates of LGD and PA mutations according to the absence or presence of a reported severe neuropsychiatric phenotype.
Compared the rates of mutations located in specific functional
domains of the SERCA2 protein according to the absence or presence of a reported severe neuropsychiatric phenotype.
A severe neuropsychiatric phenotype was rated as present if the index case and/or a family member with DD was reported as having a diagnosis of bipolar disorder, schizophrenia, or affective psychosis. All members of the same family will have the same DD causing mutation and therefore a shared diathesis. Within this analysis, we also included an unpublished missense mutation (P312R) identified in an individual with DD and bipolar disorder seen by our research group as part of our ongoing mood disorders research program who was not included in the current study as they were identified on the basis of having bipolar disorder rather than on the basis of having DD.
| Statistical analyses
Groups were compared using Chi-Square Figure 1 ; Table 2 ).
We observed possible clustering of mutations according to individuals with similar neuropsychiatric phenotypes (Figure 2 ), but none reached statistical significance:
1. All four individuals with mutations located in the functional "A" domain between the Stalk 2 and Stalk 3 domains of the protein had a history of a psychiatric disorder severe enough to warrant contact with psychiatric services (IDs 11, 12, 13, and 14).
2. Three individuals with the same missense mutation at one of the seven Ca 2+ binding sites in the M5 domain all had a DSM-IV diagnosis of a mood disorder (IDs 54, 55, and 56).
3. Two individuals with frameshift mutations one base pair apart in the S4 (Stalk 4) domain of the protein both had a history of suicide attempts in addition to having idiopathic epilepsy (ID 19) and an extensive psychiatric history including major depressive disorder and investigations for a blackout (ID 20).
| Analysis of combined data with existing literature (384 cases)
In the combined analysis with existing literature, the rate of LGD mutations was significantly higher where a history of a severe neuropsychiatric phenotype (bipolar disorder, schizophrenia, or affective psychosis) was reported in either the index case and/or family member with DD compared those without a reported history; 68% versus 40.5%, p = .011 (OR 3.15, 95% CI 1.25-7.91; When this analysis was narrowed down further to only include PA, mutations became more significant: 43% versus 4%, Fisher's = 0.003 (OR 19.22, . A summary of all mutations identified by our research group and those in the literature located within the S4-M4 region is presented in Figure 3 
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LGD Note. LGD = likely gene disrupting; PA = protein-altering; NOS = not otherwise specified; Sn = stalk domains; Mn = transmembrane domains; A domain = actuator domain; N domain = nucleotide binding; P domain = phosphorylation domain. a Requiring contact with psychiatric services. b Mutation identified in previous study (Sakuntabhai, Ruiz-Perez, et al., 1999) . c Classified as a maladjustment reaction as the patient was referred and seen by secondary psychiatric services.
FIGURE 1
Comparison of prevalence of likely gene-disrupting (LGD) and protein-altering (PA) mutations among 75 individuals with and without the lifetime occurrence of neuropsychiatric phenotypes recent prior report (Nakamura et al., 2016) , we found that LGD mutations were relatively more common in those DD individuals with neuropsychiatric phenotypes than those without such phenotypes. We had only four cases in our sample that met the prior report's definition of "psychosis" (bipolar disorder, schizophrenia, and affective psychosis). Of these four cases, three had LGD mutations and one had a PA mutation. Because of the small numbers, this difference compared to those with DD without "psychosis" does not meet statistical significance. However, when we add our new data to the existing literature, the statistical significance of the finding that the rate of LGD mutations is higher among cases/families with this severely defined neuropsychiatric phenotype is strengthened (p = .011, compared with the previously reported p = .026 [Nakamura et al., 2016] which although, included our cases the neuropsychiatric features associated with the mutations were unknown to the authors), and this association remains significant even when the phenotype definition is narrowed to include only bipolar disorder. We also observed in our sample that mutations in individuals with similar neuropsychiatric phenotypes tended to cluster in certain locations within the SERCA2 protein but none reached statistical significance. In our combined analysis, we did however find a significant relationship with mutations located in the S4-M4 region of the protein and the presence of a severe neuropsychiatric phenotype. Furthermore, when this analysis was repeated with only PA mutations the association remained significant. This finding has not previously been reported.
It is highly plausible that mutations in ATP2A2 could be involved in conferring susceptibility to neuropsychiatric illness because the gene is widely expressed in the brain. The dual role of the SERCA2b 
LGD 25 No n (%) 4 (57) 205 (96) Note. DD = Darier disease; OR = odds ratio; CI = confidence interval. n's vary because of four mutations in the literature that could not be classified according to type because of unknown function.
FIGURE 3 All known neuropsychiatric features in individuals/families with Darier disease causing mutations in the S4-M4 domain of SERCA2 including cases in current study. ER = endoplasmic reticulum, S = stalk domain, M = transmembrane domain, NOS = not otherwise specified.
Mutations have been found to be unique to families, except for mutations marked 2 where mutations have been reported in two unrelated families. a Unpublished mutation identified in an individual with DD seen by our research group who was not included in the current study. Parent of index was admitted to psychiatric hospital with "high mood" although neither parent was reported to have DD. All mutations are located in Exon 8 protein in intracellular Ca 2+ signaling and in the synthesis and posttranslational modification of proteins within the ER also provides support for this suggestion. Intracellular Ca 2+ signaling has been shown to play a role in a range of neuronal functions including neuronal excitability, neurotransmitter release, gene expression, neuronal growth, and synaptic plasticity (Berridge, 2002; Berridge, Bootman, & Lipp, 1998; Verkhratsky, 2005) . Genome-wide association studies (GWAS) have suggested the role of calcium signaling and calcium-channel activity in the pathogenesis of a number of major psychiatric disorders, including bipolar disorder and schizophrenia (Cross-Disorder
Group of the Psychiatric Genomics Consortium & Genetic Risk Outcome of Psychosis (GROUP) Consortium, 2013; Ferreira et al., 2008) with a more recent GWAS identifying ATP2A2 as a schizophreniaassociated loci (Ripke et al., 2014) .
A recent study showing Darier keratinocytes display the hallmarks of constitutive ER stress with increased sensitivity to ER stressors lead the authors of the study to suggest DD should be classed as an ER stress related disease (Savignac, Simon, Edir, Guibbal, & Hovnanian, 2014) . There is also evidence for the role of ER stress responses in neuropsychiatric disorders. Lymphoblastoid cell lines from individuals with bipolar disorder have showed an impaired response to ER stress (Hayashi et al., 2009; Pfaffenseller et al., 2014; So, Warsh, & Li, 2007) .
Lithium is the main mood stabilizer used in the treatment of bipolar disorder and a recent study identified the response to ER stress as a lithium-regulated gene network (Breen et al., 2016) . It is possible that the function of SERCA2b pumps may be more critical in the skin and the brain than in other tissues. Both tissues may have a particular susceptibility to a reduction in SERCA2b activity possibly relating to changes in ER Ca 2+ concentration and ER functioning.
A limitation of the current analysis is that despite being the largest study to date, the small stratified group sizes in our genotype- 
